Randomized phase II study comparing Gemcitabine chemoradiotherapy with Gemcitabine chemotherapy for unresectable locally advanced pancreatic cancer.
- Conditions
- nresectable locally advanced pancreatic cancer.
- Registration Number
- JPRN-UMIN000012253
- Lead Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Not provided
1) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings. 2) Watery diarrhea 3) Severe infection 4) Severe complication (heart failure, renal failure, hepatic insufficiency,hemorrhagic peptic ulcer, intestines paralysis,ileus or uncontrolled diabetes etc) 5) Massive pleural or abdominal effusion. 6) Metastasis to central nervous system. 7) Active synchronous or metachronous malignancy other than carcinoma in situ. 8) Regular use of frucitocin, fenitoin or warfarin 9) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 10) Severe mental illness 11) Patients who are judged inappropriate for the entry into the study by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two year survival rate
- Secondary Outcome Measures
Name Time Method Progression free survival(PFS) Overall Survival(OS) Adverse events Response rate